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Abstract
Background: Human monocyte-derived DC (mDC) loaded with peptides, protein, tumor cell
lysates, or tumor cell RNA, are being tested as vaccines against multiple human malignancies and
viral infection with great promise. One of the factors that has limited more widespread use of these
vaccines is the need to generate mDC in large scale. Current methods for the large-scale cultivation
of mDC in static culture vessels are labor- and time- intensive, and also require many culture
vessels. Here, we describe a new method for the large-scale generation of human mDC from
human PBMC from leukopheresis or buffy coat products using roller bottles, never attempted
before for mDC generation. We have tested this technology using 850 cm2 roller bottles compared
to conventional T-175 flat-bottom static culture flasks.
Methods: DC were generated from adherent human PBMC from buffy coats or leukopherisis
products using GM-CSF and IL-4 in T-175 static flasks or 850 cm2 roller bottles. The cells were
matured over two days, harvested and analyzed for cell yield and mature DC phenotype by flow
cytometry, and then functionally analyzed for their ability to activate allogeneic T-cell or recall
antigen peptide-specific T-cell responses.
Results: Monocytes were found to adhere inside roller bottles to the same extent as in static
culture flasks. The phenotype and function of the mDC harvested after maturation from both type
of culture systems were similar. The yield of mDC from input PBMC in the roller bottle system
was similar as in the static flask system. However, each 850 cm2 roller bottle could be seeded with
4–5 times more input PBMC and could yield 4–5 times as many mDC per culture vessel than the
static flasks as a result.
Conclusion: Our results indicate that the roller bottle technology can generate similar numbers
of mDC from adherent PBMC as traditional static flask methods, but with having to use fewer
culture vessels. Thus, this may be a more practical method to generate mDC in large-scale cutting
down on the amount of laboratory manipulations, and can save both time and labor costs.
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Background
Dendritic cells (DC) are the most potent antigen-present-
ing cells (APC) in the immune system that are the key cells
activating T-cell-based immune responses against viral
disease and cancer [1]. Recently, this powerful ability of
DC is being tested as an active vaccine approach to treat
cancer and viral infections such as HIV and CMV [2,3].
Most of these studies use monocyte-derived DC (mDC)
loaded with antigen in vitro and then injected subcutane-
ously or intravenously [4]. The most commonly used
method to generate mDC is to adhere monocytes on to
plastic in static flasks from PBMC followed by culture with
GM-CSF and IL-4 and maturation using any one of a
number of cocktails of pro-inflammatory cytokines (IL-
1β, TNF-α, IL-6) or Toll-like receptor (TLR) agonists such
as LPS [1,2]. Antigen-loaded DC vaccines have been tested
in multiple malignancies, including melanoma, breast
cancer, prostate cancer, renal cancer, and follicular lym-
phoma, where they have been found to consistently
induce antigen-specific CD4+ and CD8+ T-cell responses
along with some reported clinical response [5-7].
The production of DC vaccines requires the cultivation of
millions of clinical-grade mDC in large-scale. In some
cases more than a billion mDC may be required to ensure
that enough vaccine can be produced for multiple patient
immunizations over a number of months. Vaccination
regimens using antigen-pulsed mDC have ranged from
multiple 10–20 × 106 mDC to up to 100 × 106 or more
mDC injected subcutaneously or intravenously, respec-
tively [8,9]. Monocytes differentiate directly into DC in
these cultures and do not divide and, as a result, leuko-
pheresis products containing billions of PBMC are
required as starting material to have enough monoytes
available for the procedure. Current methods for large-
scale cultivation of mDC in static culture systems can be
cumbersome, labor- and time- intensive, and require
many repetitive culture vessels or multi-layered systems
[10-13]. The numerous manipulations required to set-up
most static culture flasks for large-scale mDC generation
also increases the chances for product variability from cul-
ture to culture and sterility being compromised. Although
non-adherent cell culture systems of isolated CD14+
monocytes have been introduced, there is still some
debate on the quality of these mDC versus those derived
from adherent populations. For example, some studies of
have found decreased yields of mature CD83+ mDC or
reduced IL-12 production capability versus adherent sys-
tems [14,15]. Thus, any improvements in the speed and
ease of generating DC from adherent monocytes in large
scale and better purity for clinical use would be a great
asset.
We describe a novel method of generating mature mDC in
large-scale using roller bottle culture technology never
before reported to be used to generate DC before. The
monocytes from the peripheral blood mononuclear cell
(PBMC) or leukopheresis preparations were adhered to
the inside surface of roller bottles on a roller apparatus at
low speed. After removal of the non-adherent cells, DC
cells are generated using culture medium containing GM-
CSF and IL-4 and matured using any one of a number of
well-defined defined cytokine cocktails. This resulted in a
large number of floating non-adherent mature DC that
can be easily harvested and used for vaccines or other pur-
poses. The roller bottle DC had similar phenotypic and
functional characteristics as those produced in static cul-
ture flasks. Overall, the roller bottle system is a self-con-
tained system requiring minimal manipulation during
culture set-up. The result is faster culture set-up times and
less labor for lab personnel than traditional static culture
methods in flat-bottom culture flasks.
Methods
Reagents and equipment
Human recombinant cytokines (GM-CSF, IL-4, IL-1β,
TNF-α, and IL-6) were purchased from R&D Systems
(Minneapolis, MN). Prostaglandin E2 (PGE2) was pur-
chased from Sigma-Aldrich (St. Louis, MO). Dendritic cell
culture medium (DC-CM) consisted of Iscove's Modified
Dulbecco's Medium (IMDM) containing Glutamax, 20
µg/ml gentamycin, 50 µM 2-mercaptoethanol (all from
Invitrogen, Carlsbad, CA), and 2% normal human AB
serum (Valley Biomedical, Winchester, VA). Roller bottles
(850 cm2 or 490 cm2) with vented caps were obtained
from Fisher-Costar (Houston, TX). A Stovall Low Profile
Roller apparatus (Stovall Life Science Inc., Greensboro,
NC) was used for the roller bottle cultures. Flat-bottom
static T-175 culture flasks (175 cm2 area) with vented caps
were obtained from Nunc (Rochester, NY). All flow
cytometry antibodies and 7-aminoactinomycin D (7-
AAD) were purchased from BD Biosciences (La Jolla, CA).
Sources of PBMC for DC generation
PBMC were obtained from peripheral blood leukopher-
esis products obtained from non-mobilized normal
donors (LifeBlood, Memphis, TN), or G-CSF-mobilized
normal donors (AllCells, Berkeley, CA). Products were
collected in the presence of Anticoagulant Citrate Dex-
trose Formula A (Gambro). In addition, peripheral blood
buffy coats (Gulf Coast Regional Blood Bank, Houston,
TX) were also used for some experiments. In some experi-
ments HLA-A*0201+ positive non-mobilized leukopher-
esis products were used to generate DC (LifeBlood,
Memphis, TN). The HLA-A*0201 status was further con-
firmed by flow cytometry after receipt of the sample in the
laboratory. All leukopheresis products and buffy coats
were used within 24 hours post-collection. The PBMC
were isolated by diluting with HBSS, centrifuged at 400 ×
g for 20 min over Histopaque-1077 (Sigma-Aldrich). TheJournal of Immune Based Therapies and Vaccines 2008, 6:1 http://www.jibtherapies.com/content/6/1/1
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interface cells were collected, pooled, and washed with
HBSS until the contaminating platelets were removed.
PBMC not used immediately were frozen in human AB
serum with 10% DMSO (33.3 × 106) cells/ml and stored
in the vapor phase of liquid nitrogen.
Dendritic cell culture in roller bottles
Washed PBMC from leukopheresis products or buffy coats
were diluted to 30 × 106 cells/ml in DC-CM and 30 ml
(900 × 106 cells) were seeded into 850 cm2 roller bottles
with vented caps (Fisher-Costar, Houston, TX). The bot-
tles were placed on the roller bottle apparatus in a 37°C,
5% CO2 incubator and rolled at low speed (1 rpm) for 2
to 3 h. The bottles were then taken out and agitated to
loosen any non-adherent cells and the floating cells
removed. The bottles were then washed 2 times with 80–
100 ml warm DC-CM by rolling the bottle inside a lami-
nar flow hood. After removal of the second wash, 150–
180 ml of DC-CM containing 1,000 U/ml GM-CSF and
1,000 U/ml IL-4 was added to each bottle. The bottles
were placed back on the roller bottle apparatus in the
incubator and rolled at 2 rpm for 4–5 days. A dendritic
cell maturation cocktail consisting of a final concentration
of 10 ng/ml IL-1β, 10 ng/ml TNF-α, 15 ng/ml IL-6, and 1
µg/ml PGE2 (ITIP) [13,16]. After 20–24 h the floating cells
were harvested in all bottles and analyzed for mature DC
content. In some experiments, an alternative maturation
cocktail called the "Pittsburgh Protocol" (25 ng/ml IL-1β,
50 ng/ml TNF-α, 1,000 U/ml IFN-γ, 20 µg/ml poly I:C,
and 3,000 U/ml IFN-α) was used to generate so-called α
Type-1DC (α DC1) was added on day 4 or 5 [17]. In some
experiments, 450 cm2 roller bottles (Fisher-Costar) were
used with PBMC seeded at 250 to 450 × 106 cells per bot-
tle.
Dendritic cell generation in flat-bottom static T-175 flasks
Washed PBMC from leukopheresis products or buffy coats
were seeded into T-175 culture flasks in 15 ml of DC-CM
(175 × 106 cells per flask). The flasks were incubated as
above for 2 to 3 h and non-adherent cells were removed.
The flasks were then washed with 50 ml of warm DC-CM
and 60 ml of DC-CM containing 800 U/ml GM-CSF and
1,000 U/ml IL-4 was added. The cells were incubated for
4–5 days and matured for 20–24 h and analyzed for
mature DC content and function as above.
Determination of mDC yield and phenotype
Isolated cells were washed in DC-CM and viable cell
recovery determined with Trypan Blue staining and count-
ing live cells on a hemocytometer using a light micro-
scope. The total floating cells isolated were divided by the
number of culture vessels to determine the yield per flask
or per bottle. For cell surface staining, the cells were
washed 2 times in cold FACS Wash Buffer (FWB) consist-
ing of D-PBS, 1% BSA and re-suspended at 10 × 106/ml in
cold FACS Stain Buffer (FSB) consisting of D-PBS, 1%
BSA, and 5% normal goat serum. The cells were stained
using anti-CD83-PE, anti-CD80-FITC, anti-CD86-APC,
CD11c-FITC and CD14-PE (all from BD Biosciences, La
Jolla, CA) on ice for 20 min and washed with cold FWB
and re-suspended in 0.35 ml cold FWB. 7-AAD (2 µg/ml)
was added 5–10 min before FACS analysis to exclude dead
cells and enumerate mDC viability. The samples were run
on a FACScalibur or FACScanto flow cytometer and ana-
lyzed using FlowJo 7.2.2 software (Tree Star Inc., Ashland,
OR).
Functional analysis of isolated mDC
DC isolated from roller bottles and static flask cultures
were assayed for their ability to induce allo-antigen T-cell
responses and CD8+ T-cell recall responses against HLA-
A2-binding epitopes from flu, CMV, and EBV [18]. For
allo-antigen responses, 50,000 monocyte-depleted PBMC
(2-hour plastic-non-adherent PBMC) from a normal
donor other than that used to generate the DC were incu-
bated in U-bottom 96-well plates with different numbers
of DC or PBMC stimulators (50,000, 25,000, 10,000,
5,000, 1,000, 500, 200, or 100 cells). On day 6, 1 µCi/well
of 3H-thymidine was added to each well and the cells har-
vested the next day and total cpm/well determined. Recall
antigen CD8+  T-cell responses were done in ELISPOT
plates (Millipore) using 5 × 105 monocyte-depleted autol-
ogous PBMC incubated with peptide-pulsed mDC har-
vested from roller bottles or static flask cultures. The mDC
were pulsed with 5 µg/ml of the HLA-A2-binding epitopes
from influenza A matrix (GILGFVFTL), CMV pp65 (NLVP-
MVATV), and EBV BMLF1 (GLCTLVAML) for 90 min,
washed and added to the responder cells in the ELISPOT
plates [18]. The plates were incubated overnight and proc-
essed as described before [19].
Results
Monocytes adhere similarly in roller bottles and static 
flasks
We first tested whether human monocytes can adhere
inside roller bottles as in traditional static flat-bottom
flasks. PBMC from normal donor buffy coats were seeded
into 490 cm2 roller bottles or T-175 culture flasks and
adhered for 2.5 h (1 rpm for the roller bottles) in the incu-
bator. The non-adherent cells were collected and stained
for CD14 and CD3 expression. Adherence of monocytes
will deplete the CD14+ population in the non-adherent
cell suspension. As shown in Table 1, the CD14+ mono-
cytes adhered in roller bottles with similar efficiency as
flat-bottom T-175 flasks, as indicated by the drop in per-
centage of CD14+ cells in the suspended cell fraction.Journal of Immune Based Therapies and Vaccines 2008, 6:1 http://www.jibtherapies.com/content/6/1/1
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Table 1: Adherence of peripheral blood CD14+ monocytes to roller bottles and static flasks*
Condition CD14+ (%) CD3+ (%) CD14- and CD3- (%)
Pre-adherent PBMC 14.6 45.4 40
Flask: Post-adherence 2 59.5 38.4
Roller bottle #1: Post-adherence 2.2 55.2 36.4
Roller bottle #2: Post-adherence 2.1 56 41.9
*PBMC isolated from a normal donor buffy coat donor were incubated in T-175 culture flask or 450 cm2 roller bottles for 2.5 h. The roller bottles 
were rolled at low speed (1 rpm). The non-adherent cells were isolated and stained along with a sample of the original PBMC for CD14 and CD3 
expression. The percent CD14+, CD3+, or CD14-CD3- cells are shown before (pre-adherent PBMC) and after the adherence protocol.
Generation of phenotypically mature mDC from adherent monocytes using ITIP in roller bottle cultures in comparison to  static flask cultures Figure 1
Generation of phenotypically mature mDC from adherent monocytes using ITIP in roller bottle cultures in 
comparison to static flask cultures. PBMC from a normal donor leukopheresis product was seeded into 850 cm2 roller 
bottles or into T-175 flasks and the monocytes adhered for 2.5 h as described in the Methods section. After washing out the 
non-adherent cells in both systems, the cells were cultured for 4 days with 1,000 U/ml GM-CSF and 1,000 U/ml IL-4 and then 
matured using ITIP. The floating cells were harvested after 24 h and stained for CD11c, CD14, HLA class II DP, DQ, DR, 
CD83, CD86, and CD80. The unstained and stained populations in the histograms are shown in grey and red, respectively. In 
the case of CD86 and CD83 staining, the surface expression on cells from non-matured cultures (in blue) is shown as a com-
parison to verify that maturation was induced in both systems. The results of one out of 3 similar experiments are shown.
ITIP Maturation
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ITIP Maturation
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Similar degree of DC maturation in roller bottles as in 
static flasks
Next, we generated monocyte-derived DC in 850 cm2
roller bottles versus T-175 static flasks after monocyte
adherence and assessed the phenotype and viability of the
DC generated from each culture type after maturation
with 10 ng/ml IL-1β, 10 ng/ml TNF-α, 15 ng/ml IL-6, and
1 µg/ml PGE2 (ITIP). The floating cells isolated from both
culture types 24 h after addition of the maturation cock-
tail were stained for CD83, CD86, CD80, CD11c, and
CD14 and analyzed by FACS. Both types of cultures
induced comparable levels of DC maturation, as indicated
by the similar percentages of CD83+, CD80+, CD86hi,
CD11c+, CD14-/lo generated using two separate methods,
ITIP maturation (Fig. 1) and Pittsburgh Protocol matura-
tion (Fig. 2). The viability of the harvested mature DC
from the roller bottles and static flasks was also assessed
using 7-AAD staining of the cells prior to FACS analysis. In
both cases, the CD83+ DC were > 90% viable, as shown in
the two separate experiments shown in Fig. 3.
Generation of phenotypically mature mDC from adherent monocytes using the Pittsburgh Protocol in roller bottle cultures in  comparison to static flask cultures Figure 2
Generation of phenotypically mature mDC from adherent monocytes using the Pittsburgh Protocol in roller 
bottle cultures in comparison to static flask cultures. PBMC from a normal donor leukopheresis product was seeded 
into 850 cm2 roller bottles or into T-175 flasks and the monocytes adhered for 2.5 h as described in the Methods section. After 
washing out the non-adherent cells in both systems, the cells were cultured for 4 days with 1,000 U/ml GM-CSF and 1,000 U/
ml IL-4 and then matured using the Pittsburgh Protocol combination of cytokines. The floating cells were harvested after 24 h 
and stained for CD11c, CD14, HLA class II DP, DQ, DR, CD83, CD86, and CD80. The unstained and stained populations in 
the histograms are shown in grey and red, respectively. In the case of CD86 and CD83 staining, the surface expression on cells 
from non-matured cultures (in blue) is shown as a comparison to verify that maturation was induced in both systems. The 
results of one out of 3 similar experiments are shown.
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Efficiency in generating large numbers of mature DC in 
roller bottles
One of the benefits of using culture vessels with increased
surface area such as roller bottles is maximizing the scale
in which DC cells can be generated while minimizing the
number of separate culture vessels needed to achieve
high-throughput production. Using 850 cm2 roller bottles
we found that up to 900 × 106 PBMC could be loaded dur-
ing the monocyte adherence step, while up to 180 × 106
cells could be loaded in T-175 flasks. We determined the
yield of total floating cells and mature DC recovered in
both culture systems. In these experiments, PBMC from
G-CSF-mobilized or non-mobilized leukopheresis prod-
ucts were loaded into the culture vessels and adherent
cells treated with GM-CSF and IL-4 for 4 to 5 days fol-
lowed by treatment with the ITIP maturation cocktail or α
DC1 maturation cocktail (not shown) for 24 h. Table 2
shows the results of three separate experiments comparing
Roller bottle cultures yield mature CD83+ DC with high viability Figure 3
Roller bottle cultures yield mature CD83+ DC with high viability. Mature mDC were generated in 850 cm2 roller bot-
tles or in T-175 static flasks as before using ITIP maturation. The floating cells were harvested and stained for DC maturation 
markers without fixation. Immediately before FACS analysis 2 µg/ml 7-ADD was added as viability indicator. The dot plots 
shown the total cells in the floating fractions with the CD83+, 7-AAD- and CD83+, 7-AAD+ cells gated. In both cases, the 
CD83+ cells exhibited 94–96% viability. The results of two separate experiments are shown.
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the yield of mature DC in both systems and the percentage
of mature DC relative to the original PBMC load. On aver-
age, from normal donor non-GSF-mobilized leukopher-
esis products a single 850 cm2 roller bottle culture yielded
80–85 × 106 CD83+ CD86hi DC and the static T-175 flasks
yielded up to 10–20 × 106CD83+ CD86hi DC; this repre-
sent an average 5 to 6-fold more mDC per single culture
vessel (Table 2). In addition, DC from both types of cul-
tures were able to be cryopreserved in 90% AB serum,
10% DMSO with > 80% viability after thawing (data not
shown). The roller bottle system could also generate mDC
from G-CSF-mobilized leukopheresis products with a
similar yield as static flasks (Table 2; Experiment #3). In
this case, the yield of mDC per input cells was lower
because of the lower percentage of mature CD14+ mono-
cytes in these products than in non-mobilized PBMC.
Similar relative results were obtained with the Pittsburgh
Protocol maturation protocol (data not shown). Thus, the
roller bottle approach allows for the efficient scale-up for
Table 2: Yield of mature DC from roller bottle cultures and static flask cultures*
Expt # Culture system PBMC seeded per 
vessel
Average floating cells 
recovered
Average mature DC 
(CD83+, CD86hi) 
recovered
% yield of mature DC
1** 850 cm2 roller bottles 900 × 106 106 × 106 85 × 106 9.4%
T-175 static flasks 180 × 106 20 × 106 19.2 × 106 10.7%
2** 850 cm2 roller bottles 900 × 106 100 × 106 82 × 106 9.1%
T-175 static flasks 180 × 106 16 × 106 10.2 × 106 5.7%
3*** 850 cm2 roller bottles 800 × 106 84 × 106 23 × 106 2.9%
T-175 static flasks 200 × 106 29 × 106 6 × 106 3%
*Human peripheral blood leukopheresis products were seeded and monocytes adhered in the two types of culture vessels, as described in the 
Methods section. After 4 to 5 days of culture with GM-CSF and IL-4, ITIP cocktail was added to induce DC maturation. On average, 2–3 roller 
bottles or static flasks were set up for each experiment. The floating cells were harvested one day later and viable cellrecovery was determined by 
Trypan Blue staining with a hemocytometer followed by FACS staining for CD83 and CD86. The number of mature DC was calculated from the 
percent CD83+, CD86hi cells using the total number of viable floating cells. The results of three separate experiments are shown.
**Experiment was done directly with normal donor non-G-CSF-mobilized leukopheresis products.
***Experiment was done directly with a G-CSF-mobilized normal donor leukopheresis product, accounting for the lower yield of mature DC.
Phenotypic analysis of DC purity in non-matured DC cultures from roller bottle and static flask cultures Figure 4
Phenotypic analysis of DC purity in non-matured DC cultures from roller bottle and static flask cultures. DC 
were generated as before in 850 cm2 roller bottles or T-175 static flasks for 4 days and then incubated for an additional 24 h 
without any additional cytokines ("Not matured"). The floating cells were harvested after this additional 24 h incubation and 
stained for CD11c, CD13, CD14, CD83 and CD86 and analyzed by flow cytometry. In each case all the isolated floating cells 
were analyzed without gating and phenotype of DC compared between the roller bottles and static flask system. The numbers 
in the dot plots indicate the percentage of cells out of the total population of floating cells having the indicated phenotype. The 
results of one out of 4 similar experiments are shown.
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the generation of large numbers of mature DC with simi-
lar yield of mDC per input cells as in static flasks.
The generation of DC from adherent PBMC from periph-
eral blood does not yield a 100% pure population of
floating mature DC. The mDC are mixed with other cells
that are carried over from the original PBMC loaded into
the culture vessels during the monocyte adherence step.
We determined the percentage of CD83+, CD11c+, CD13+,
and CD14+ in the high forward scatter (FSChi) and high
side scatter (SSChi) population (DC gate), as well as the
low forward scatter (FSClo) and low side scatter (SSClo)
population isolated from non-matured (Fig. 4) and ITIP-
matured (Fig. 5) cultures from both the static flask and
roller bottle systems. The flow cytometry profiles in Fig. 4
and Fig. 5 are all on total (ungated) cells in each sample.
CD83 was highly induced in the FSChi, SSChi population
in the ITIP matured cultures from both the flask and roller
bottle systems (Fig. 5), while none of FSClo, SSClo cells
expressed these high CD83 levels (Fig. 5). In addition,
only the FSChi, SSChi  population was CD11c+  in the
matured cultures from both system, with only a small
fraction (< 1%) of FSClo, SSClo cells expressing CD11c
(Fig. 5). The FSClo, SSClo cells were further analyzed and
found to consist largely of CD13-, CD14- (non-myeloid
origin) and CD11c- cells which by process of elimination
are essentially lymphocytes (T and B cells) or NK cells.
Some FSClo, SSClo cells having low CD13 expression were
found in the non-matured cultures (Fig. 4), but these
largely disappeared in the ITIP-matured cultures (Fig. 5)
with mostly a minor population CD13-, CD14-, CD11c-
population making up the FSClo, SSClo population. In the
matured cultures from both the flasks and roller bottles,
the FSClo, SSClo, CD13- subset was less than 10% in each
case (Fig. 5). Lastly, CD14 was down-modulated in cells
obtained from both ITIP-matured static flasks and roller
bottles (Fig. 5), as compared to cells isolated from non-
matured cultures (Fig. 4).
Thus, both roller bottle and static flask cultures yielded
mature DC of similar purity with a similar minor popula-
tion of FSClo, SSClo cells having a lymphocyte (CD11c-,
CD13-, CD14-) phenotype.
DC generated in roller bottles function similarly as those 
from static flasks
In order to determine whether DC generated in roller bot-
tles functioned similarly as antigen-presenting cells (APC)
as those generated in static flasks, we tested both types of
DC for their ability to activate allo-specific and autolo-
gous recall antigen peptide-specific T cell responses. DC
were generated in 850 cm2 roller bottles or T-175 static
culture flasks as before and the floating cells were isolated
and tested for APC activity. Fig. 6 shows an example of the
allo-stimulatory function of DC generated from a normal
leukopheresis donor (APH 10) in roller bottles versus
Phenotypic analysis of DC purity in matured DC cultures from roller bottle and static flask cultures Figure 5
Phenotypic analysis of DC purity in matured DC cultures from roller bottle and static flask cultures. DC were 
generated as before in 850 cm2 roller bottles or T-175 static flasks for 4 days and then incubated for an additional 24 h with 
ITIP cocktail to induce DC maturation ("Matured-ITIP"). The floating cells were harvested after 24 h after addition of the ITIP 
maturation cocktail and stained for CD11c, CD13, CD14, CD83 and CD86 and analyzed by flow cytometry. In each case all 
the isolated floating cells were analyzed without gating and phenotype of DC compared between the roller bottles and static 
flask system. The numbers in the dot plots indicate the percentage of cells out of the total population of floating cells having the 
indicated phenotype. The results of one out of 4 similar experiments are shown.
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static flasks. In both cases, the DC induced a similar rate
of allo-specific T-cell proliferation at the different DC
doses used in the assay (Fig. 6). Floating cells isolated
from non-matured roller bottle DC cultures as well as the
original PBMC population has substantially lower allo-
stimulatory activity on a per cell basis than the mature DC
(Fig. 6). In another experiment, we found that both the
ITIP and α DC1 maturation protocols in roller bottles
induced DC of comparable potent allo-stimulatory capac-
ity in comparison to the original starting PBMC popula-
tion in the leukopheresis product (data not shown). To
test the ability of DC to present peptides and activate
autologous T cells, we used a recall antigen response assay
using HLA-A*0201-binding peptides. In this case, we gen-
erated DC in 850 cm2 roller bottles or T-175 static flasks
from HLA-A*0201+ donor leukopheresis products. The
floating DC after the maturation step were isolated and
pulsed with 9-mer peptides from flu, CMV, and EBV (see
Materials and Methods). The peptide-pulsed DC were
washed and incubated with autologous monocyte-
depleted PBMC in an overnight IFN-γ ELISPOT assay
(1:50 or 1:100 DC to responder ratios). As shown in Fig.
7, mature DC generated using either approach yielded
cells of comparable APC activity in terms of the number
of IFN-γ spot-forming cells in the assay. Little or no IFN-γ
production was found in cultures with non-preloaded
DC, or in cultures without added DC (Fig. 7). Thus, DC
generated in roller bottles yield highly competent APC for
T-cell stimulation.
Discussion
The generation of large numbers of mature DC in a large-
scale culture processes for application in vaccine clinical
trials still remains a challenge using present static flask
technology due to the high number of culture vessels
needed. Although new devices such as multi-level static
culture devices such as Cell Factories™ (Nunc, Rochester,
NY) have improved our ability to generate DC in large
scale, most static culture systems are still cumbersome and
labor intensive [4,11,13]. We have developed an alterna-
tive approach for the large-scale generation of mature DC
from adherent human monocytes using roller bottle tech-
nology. This system can generate DC from plastic-adher-
ent monocytes as traditional static flask cultures. The DC
generated using roller bottles had the same phenotypic
and functional attributes as those generated in static flask
cultures. However, given the large surface area in a single
roller bottle (850 cm2), this technology allows for the
loading of much higher numbers of input PBMC per sin-
gle vessel with a comparable level of monocyte adherence
Dendritic cells generated in roller bottle cultures have potent allo-stimulatory capability Figure 6
Dendritic cells generated in roller bottle cultures have potent allo-stimulatory capability. Dendritic cells were 
generated in 850 cm2 roller bottles or T-175 static flasks as before using ITIP maturation. The floating cells were harvested, 
irradiated at 20 Gy and mixed with 50,000 allogeneic T-cell-enriched PBMC (plastic non-adherent PBMC) at different stimula-
tor to responder ratios in 96-well plates. After 5 days, 1 µCi/well of 3H-thymidine was added to each well and the plates har-
vested 18 h later. Irradiated PBMC from the original DC donor were also used as stimulators as a control. The average cpm 
and standard deviation of triplicate cultures are shown for each stimulator type.
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and mature DC yield, thereby generating much higher
numbers of DC per vessel. A number of benefits arise out
of this approach, including the need for up to 5 times less
culture vessels to generate the equal number of DC versus
static T-175 flasks. The roller bottle method is also easy to
perform, more practical than handling large numbers of
flasks, and overall saves technician time and potential
labor costs. In addition, the less manipulation required to
generate DC products in large scale will also help ensure
less chance of error and contamination with infectious
agents that would destroy the product.
In our initial experiments, we found that monocytes had
a similar capacity to adhere to the plastic inside the roller
bottles as in the static flasks. Initially, this was a surprise
to us, considering the dogma in the field that has emerged
with the use of static culture flasks to generate DC for over
15 years. However, in our loading step the PBMC are
rolled in the bottles at sufficiently low speed (1 rpm)
allowing the monocytes to adhere just as well as in static
flasks. The low volume per vessel surface area used during
the loading process in the bottles allows the monocytes to
roll along and stay in close contact with the surface and
then eventually attach. This is akin to the attachment of
monocytes rolling along the walls of blood vessels in the
body during extravasation into tissues.
Recently, newer static flat-bottom culture systems for DC
have been developed such as the Cell Factories™ (Nunc,
Rochester, NY) [11,13]. These systems consist of two or
more flat-bottom culture surfaces stacked on top of each
other in a single large flask format. The cells are seeded
into a main port and distributed over the multiple stacked
surface areas. We have found however that these vessels
are cumbersome to handle and it is not straightforward to
evenly distribute the cell and culture medium over all the
stacked surfaces in the culture vessel (unpublished obser-
vations). In addition, feeding additional growth factors
and DC maturation agents so that they are evenly distrib-
uted in each culture level also requires additional manip-
ulation and is not straightforward. In contrast, the roller
bottle system offers a simpler and more fool-proof
method to generate the same or even greater number of
mature DC allowing even novice technicians to set-up the
cultures with ease and higher reproducibility.
Roller bottles have been used in vaccine manufacture to
culture strongly adherent fibroblast producer lines and
have never been tested for their ability to generate mono-
cyte-derived DC in large scale. Thus, this approach is a
novel application that increases the versatlity of this tech-
nology and broadens its application in vaccine manifac-
turing. In addition, the mDC generated in roller bottles
Dendritic cells generated in roller bottles stimulate autologous peptide-specific T-cell responses Figure 7
Dendritic cells generated in roller bottles stimulate autologous peptide-specific T-cell responses. Dendritic cells 
from HLA-A*0201+ normal donor leukopheresis products were differentiated and matured with ITIP in roller bottles or static 
flasks as before. The floating cells were harvested, pooled, irradiated (20 Gy), and pulsed with HLA-A*0201 epitopes from flu, 
EBV, and CMV (see Materials and Methods for details). The DC were washed and added to 500,000 T-cell-enriched autologous 
PBMC in anti-IFN-γ antibody-coated ELISPOT plates in the numbers indicated. Each assay was run in triplicate. The plates were 
harvested after overnight culture and developed. Shown is the image taken of the developed ELISPOT plate (A) and corre-
sponding graphical representation of the number of spots per 500,000 input responder cells under the different conditions (B). 
Dendritic cells without peptide pre-pulsing were used as controls. The results are representative of two similar experiments.
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are functionally equivalent in terms of their ability to acti-
vate T-cell responses as mDC generated in static flasks.
Conclusion
The roller bottle method described here is an new and
more practical way to generate large numbers of mature
DC with potent APC activity for vaccine applications or
large scale laboratory studies where > 100 million mDC
are routinely needed. The method is easy to perform, saves
time, and generates mDC of equal potency and similar
purity as traditional static flask methods. The method can
also be easily translated into a GMP environment where
roller bottles have been used for other applications.
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